136,333 Shares in AngioDynamics, Inc. $ANGO Bought by D.A. Davidson & CO.

Key Points

• D.A. Davidson & CO. established a new stake of 136,333 shares in AngioDynamics worth approximately $1.75 million, representing about 0.33% of the company at quarter end amid overall institutional ownership of 89.43%.
• Analyst sentiment is mixed — the consensus is a “Moderate Buy” with a $18.67 target, but recent notes include downgrades and a Canaccord price-target cut to $16 while Weiss reiterated a sell rating.
• AngioDynamics stock opened at $11.16, trading in a 12‑month range of $8.36–$13.99; the company reported Q1 EPS of ($0.07) that beat estimates, revenue of $78.42M also beat consensus, but it still shows a negative net margin and ROE.

D.A. Davidson & CO. acquired a new position in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 136,333 shares of the medical instruments supplier's stock, valued at approximately $1,751,000. D.A. Davidson & CO. owned approximately 0.33% of AngioDynamics at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Farther Finance Advisors LLC raised its holdings in AngioDynamics by 146.4% during the fourth quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier's stock valued at $26,000 after buying an additional 1,199 shares in the last quarter. State of Wyoming raised its holdings in AngioDynamics by 53.6% during the third quarter. State of Wyoming now owns 4,749 shares of the medical instruments supplier's stock valued at $53,000 after buying an additional 1,658 shares in the last quarter. State of Alaska Department of Revenue bought a new position in AngioDynamics during the third quarter valued at about $25,000. Washington Trust Advisors Inc. bought a new position in AngioDynamics during the third quarter valued at about $27,000. Finally, Rhumbline Advisers raised its holdings in AngioDynamics by 4.3% during the second quarter. Rhumbline Advisers now owns 61,337 shares of the medical instruments supplier's stock valued at $608,000 after buying an additional 2,510 shares in the last quarter. 89.43% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Zacks Research downgraded AngioDynamics from a "strong-buy" rating to a "hold" rating in a research report on Monday, March 30th. Freedom Capital raised AngioDynamics to a "strong-buy" rating in a research report on Monday, April 6th. Canaccord Genuity Group lowered their price target on AngioDynamics from $18.00 to $16.00 and set a "buy" rating on the stock in a research report on Monday, April 6th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of AngioDynamics in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, AngioDynamics currently has a consensus rating of "Moderate Buy" and a consensus target price of $18.67.

AngioDynamics Stock Up 2.0%

ANGO stock opened at $11.16 on Friday. AngioDynamics, Inc. has a twelve month low of $8.36 and a twelve month high of $13.99. The company has a market cap of $461.13 million, a PE ratio of -14.88 and a beta of 0.37. The business's 50-day simple moving average is $10.81 and its 200 day simple moving average is $11.49.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its earnings results on Thursday, April 2nd. The medical instruments supplier reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 4.66% and a negative net margin of 10.01%.The business had revenue of $78.42 million for the quarter, compared to the consensus estimate of $76.77 million. On average, equities research analysts anticipate that AngioDynamics, Inc. will post -0.19 EPS for the current year.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company's products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.

Want to see what other hedge funds are holding ANGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AngioDynamics, Inc. (NASDAQ:ANGO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.